6 7 8 9

found Documents: 447

Announcements & Press Releases, Other Ventures, Press Releases | 9 Jun 2020

Chi-Med Announces US$95 million Guangzhou Land Compensation Agreement

1 item

London: Tuesday, June 9, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”), its 50:50 joint venture with Guangzhou Baiyu

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 4 Jun 2020

Chi-Med Announces the Continuation of Phase III FRUTIGA Study of Fruquintinib in Second-Line Gastric Cancer in China Following a Planned Interim Data Review

1 item

London: Thursday, June 4, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the Independent Data Monitoring Committee (IDMC) of the FRUTIGA study of fruquintinib has completed a planned interim data review.

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 1 Jun 2020

Chi-Med Plans to Submit NDA for Surufatinib Following Pre-NDA Meeting with the U.S. FDA

1 item

London: Monday June 1, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it has held its pre-New Drug Application (“NDA”) meeting with the U.S. Food and Drug Administration (“FDA”) for surufatinib f

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 May 2020

Chi-Med Announces NDA Acceptance in China for Savolitinib in the Treatment of Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations

1 item

Press Release — First NDA filing of savolitinib globally — — Chi-Med seeking first-in-class Chinese marketing authorization for a selective MET inhibitor — London: Friday, May 29, 2020: Hutchison China MediTech Limi

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 May 2020

Chi-Med to Discuss Select Global Clinical Trial Data Presented at ASCO20

1 item

Press Release ― Savolitinib in MET exon 14 skipping NSCLC efficacy evaluable patients demonstrated 49.2% ORR, 93.4% DCR and 9.6 months DoR, including 36% patients with more aggressive disease subtype ― ― Savolitinib vs. sunitinib stu

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 26 May 2020

Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and Fruquintinib with Tislelizumab

1 item

Press Release – Collaboration to explore multiple solid tumor cancer indications – – Initial development focused on multi-cohort trials in the U.S., Europe, China and Australia – LONDON, UK; CAMBRIDGE, Mass. and BEIJING

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 14 May 2020

Chi-Med Highlights Clinical Data to be Presented at the Upcoming ASCO20 Virtual Scientific Program

1 item

London: Thursday, May 14, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of savolitinib, surufatinib, and fruquintinib will be presented at the upcoming AS

Download Press Release (PDF)

Announcements & Press Releases, Group | 11 May 2020

Chi-Med to Attend Upcoming Investor Conferences

1 item

London: Monday, May 11, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate in a virtual fireside chat at the Bank of America 2020 Healt

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Coverage | 22 Apr 2020

Chi-Med Highlights Presentations of Surufatinib at the Upcoming AACR Virtual Annual Meetings

1 item

London: Wednesday, April 22, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the ongoing studies of surufatinib will be presented at the upcoming American Association for Cance

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 17 Apr 2020

Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors

1 item

London: Friday, April 17, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted two Fast Track Designations for the development of surufatinib, for

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 31 Mar 2020

Chi-Med Initiates a Phase II Trial of HMPL-453 in Patients with Advanced Malignant Mesothelioma in China

1 item

London: Tuesday, March 31, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) has initiated a Phase II study of HMPL-453, its novel small molecule inhibitor targeting fibroblast growth factor receptors (“FGFR”), in patients

Download Press Release (PDF)

Announcements & Press Releases, Group | 25 Mar 2020

2019 Annual Report and Notice of Annual General Meeting

1 item

London: Wednesday, March 25, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/ AIM: HCM) today announces that its 2019 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy (“AGM Materials”) have bee

View Announcement (PDF)

Announcements & Press Releases, Group | 3 Mar 2020

Chi-Med Reports 2019 Full Year Results and Provides Updates on Key Clinical Programs

1 item

Company to Host Annual Results Conference Call Today at 1:00 p.m. GMT / 8:00 a.m. EST / 9:00 p.m. HKT London: Tuesday, March 3, 2020: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM), a commercial-stage biopharmaceutical comp

View Announcement (PDF)

Announcements & Press Releases, Group | 25 Feb 2020

Chi-Med to announce 2019 Final Results on Tuesday, March 3, 2020 – adjustment to announcement and presentation logistics due to travel restrictions

1 item

London: Tuesday, February 25, 2020: Further to its announcement dated January 31, 2020, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced that its final results for the year ended December 31, 2019 will be released on Tuesd

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 10 Feb 2020

Chi-Med Highlights Updated Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2020 ASCO Genitourinary Cancers Symposium

1 item

Press Release London: Monday, February 10, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the availability of updated results from the Phase II CALYPSO study of the savolitinib / Imfinzi® (durvalumab) combi

Download Press Release (PDF)

Announcements & Press Releases, Group | 6 Feb 2020

Chi-Med Announces the Exercise of Underwriters’ Over-allotment Option for Public Offering of ADSs

1 item

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Thursday, February 6, 2020: Hutchiso

View Announcement (PDF)

Announcements & Press Releases, Group | 31 Jan 2020

Chi-Med to Announce 2019 Final Results

1 item

The announcement has been updated on February 25, please see the updated announcement here. London: Friday, January 31, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended Decem

View Announcement (PDF)

Announcements & Press Releases, Group | 23 Jan 2020

Chi-Med Announces Pricing of US$110 Million Public Offering of ADSs

1 item

View Announcement (PDF)

Announcements & Press Releases, Group | 21 Jan 2020

Chi-Med Announces Proposed Public Offering of ADSs

1 item

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 20 Jan 2020

Chi-Med Announces that Surufatinib Phase III SANET-p Study Has Already Achieved its Primary Endpoint in Advanced Pancreatic Neuroendocrine Tumors in China and Will Stop Early

1 item

London: Monday, January 20, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the independent Data Monitoring Committee (“IDMC”) of the Phase III pivotal study of surufatinib in advanced neuroendocrine

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 13 Jan 2020

Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors

1 item

Press Release London: Monday, January 13, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase II study in China of surufatinib in combination with Tuoyi (toripalimab) in patients with advanced solid tumors.

Download Press Release (PDF)

Announcements & Press Releases, Group, Press Releases | 6 Jan 2020

Chi-Med to Present at the 38th Annual JP Morgan Healthcare Conference

1 item

Press Release London: Monday, January 6, 2020: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 38th Annual JP Morgan Healthcare Conference on Wednes

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 20 Dec 2019

Chi-Med’s New Drug Application for Surufatinib in Non-Pancreatic Neuroendocrine Tumors Granted Priority Review in China

1 item

Press Release London: Friday, December 20, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (“NMPA”) has gran

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 28 Nov 2019

Chi-Med’s Elunate® (Fruquintinib Capsules) Included in the National Reimbursement Drug List in China

1 item

London: Thursday, November 28, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Elunate® (fruquintinib capsules), its national class 1 targeted anticancer drug for the treatment of patients with advanced

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 25 Nov 2019

Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors

1 item

London: Monday, November 25, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug designation to surufatinib for the treatment of pancr

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 23 Nov 2019

Chi-Med Highlights Oral Presentations at 2019 ESMO Asia Annual Meeting

1 item

London: Saturday, November 23, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) shared analyses from two clinical studies of savolitinib and fruquintinib at the fifth European Society for Medical Oncology Asia Congress (“ESM

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology | 11 Nov 2019

Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors

1 item

London: Monday, November 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its New Drug Application (“NDA”) for surufatinib for the treatment of patients with advanced non-pancreatic neuroendocrine

View Announcement (PDF)

Group, Press Releases | 11 Nov 2019

Chi-Med to Attend Upcoming Investor and Industry Conferences

1 item

London: Monday, November 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the following conferences: Deutsche Bank Depositary Receipts Virt

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 17 Oct 2019

Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers

1 item

London: Thursday, October 17, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today highlighted the publication of results from the Phase II VIKTORY (targeted agent eValuation In gastric cancer basKeT KORea studY) trial in Ca

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 10 Oct 2019

Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors

1 item

Suzhou, China and London, UK, Thursday, October 10, 2019 — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) and Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the expansion of their global collaboration ag

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 4 Oct 2019

Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma

1 item

London: Friday, October 4, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with relapsed or refr

Download Press Release (PDF)

Announcements & Press Releases, Group | 30 Sep 2019

CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term

1 item

View Announcement (PDF)

Announcements & Press Releases, Group | 30 Sep 2019

CK Hutchison offers 1.3% of Chi-Med’s share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term

1 item

View Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Sep 2019

Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting

1 item

Press Release – Surufatinib achieved primary endpoint, reducing the risk of progression or death by 67% in patients with non-pancreatic neuroendocrine tumors (“NET”) in the Phase III SANET-ep study – – Preparations underway for the potent

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 25 Sep 2019

Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting

1 item

– Late-Breaking Abstract of the positive SANET-ep Phase III trial of surufatinib in patients with non-pancreatic neuroendocrine tumors (“NET”) to be presented – – Conference call and webcast with lead trial investigators to be held on Mond

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 18 Sep 2019

Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting

1 item

London: Wednesday, September 18, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) shares additional analyses from three completed and ongoing clinical studies of fruquintinib and savolitinib at the 22nd Annual Meeting of the C

Download Press Release (PDF)

Announcements & Press Releases, Group, Press Releases | 3 Sep 2019

Chi-Med to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

1 item

London: Tuesday, September 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley 17th Annual Global Healthcare C

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 3 Sep 2019

Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma

1 item

London: Tuesday, September 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-689, its novel, highly selective and potent small molecule phosphoinositide-3 kinase delta

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 23 Aug 2019

Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with Immune Thrombocytopenia (ITP) in China

1 item

London: Friday, August 23, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with immune thrombocytopenia (“ITP”

Download Press Release (PDF)

Announcements & Press Releases, Group | 30 Jul 2019

Chi-Med Reports 2019 Interim Results and Provides Updates on Key Clinical Programs

1 item

London: Tuesday, July 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs. Major highlight

Download Announcement (PDF)

Announcements & Press Releases, Group | 3 Jul 2019

Chi-Med to Announce 2019 Half-Year Financial Results

1 item

London: Wednesday, July 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer Time (BST) (2:00 pm

View Announcement (PDF)

Announcements & Press Releases, Group | 28 Jun 2019

Chi-Med Announces Pricing of Upsized U.S. Public Secondary Offering of American Depositary Shares

1 item

Download Announcement (PDF)

Announcements & Press Releases, Group | 27 Jun 2019

Chi-Med Announces Secondary Offering of American Depositary Shares

1 item

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 14 Jun 2019

Chi-Med Announces that Surufatinib Phase III SANET-ep Study Has Met its Primary Endpoint at Interim Analysis in Advanced Non-Pancreatic Neuroendocrine Tumors in China and Will Stop Early

1 item

London: Friday, June 14, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the independent Data Monitoring Committee (“IDMC”) of the Phase III pivotal study of surufatinib in advanced neuroendocrine tum

Download Press Release (PDF)

Announcements & Press Releases, Group | 29 May 2019

Results of Extraordinary General Meeting

1 item

London: Wednesday, May 29, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that the ordinary resolution and special resolution put to its Extraordinary General Meeting (“EGM”) held on May 29, 2019 were dul

Download Announcement (PDF)

Announcements & Press Releases, Group | 3 May 2019

Notice of Extraordinary General Meeting and Shareholders' Circular

1 item

London: Friday, May 3, 2019: Hutchison China MediTech Limited (“Chi-Med” or “Company”) (AIM/Nasdaq: HCM) today announces that an Extraordinary General Meeting (“EGM”) is to be held at 11:00 a.m. London time on Wednesday, May 29, 2019. An

Download Announcement (PDF)

Announcements & Press Releases, Group | 15 Apr 2019

Chi-Med Files Application to List in Hong Kong and Announces Proposed Global Offering

1 item

Download Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 29 Mar 2019

Chi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China

1 item

London: Friday, March 29, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a registration-enabling Phase IIb/III study comparing surufatinib (HMPL-012 or sulfatinib) with capecitabine in patients with advanced

Download Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 28 Mar 2019

Chi-Med Highlights Oral Presentations on Savolitinib Lung Cancer Programs at AACR Annual Meeting

1 item

Press Release London: Thursday, March 28, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will share further data on the savolitinib development programs in lung cancer at the American Association of Cancer Research (AACR)

Download Press Release (PDF)

Announcements & Press Releases, Group | 21 Mar 2019

2018 Annual Report and Notice of Annual General Meeting

1 item

London: Thursday, March 21, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2018 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders

Download Announcement (PDF)

1 2 3 4

6 7 8 9